NAM CROs & testing servicesconfirmed
Charles River Laboratories
Largest preclinical CRO, repositioning around NAMs through its Alternative Methods Advancement Project while keeping in vivo capacity.
Notable
NAMs advisory board (Oct 2025); acquiring PathoQuest (2026); agreed to sell its discovery sites to IQVIA (Feb 2026). Leadership calls the shift an evolution, not a revolution.
Related deals
- Jun 18, 2026PartnershipCharles River joined Lilly's TuneLab AI/ML platform to contribute nonclinical testing expertise.Undisclosedir.criver.com(opens in new tab)
- Feb 25, 2026M&AIQVIA agreed to buy Charles River's five in vitro discovery sites and a small-molecule AI platform.
Related updates
- Jan 2026Charles River's incoming CEO calls the NAM shift an evolutionfiercebiotech.com(opens in new tab)
- Oct 15, 2025Charles River forms a NAMs scientific advisory boardir.criver.com(opens in new tab)